The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma

SIMPLE SUMMARY: Hepatocellular carcinoma is a frequent and poor prognosis tumor, with most patients facing up, soon or later, to systemic therapies. So far, systemic therapies based on tyrosine kinase inhibitor monotherapies have been of modest benefit. The aim of this review article was to characte...

Descripción completa

Detalles Bibliográficos
Autor principal: Merle, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826922/
https://www.ncbi.nlm.nih.gov/pubmed/33440630
http://dx.doi.org/10.3390/cancers13020238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826922/
https://www.ncbi.nlm.nih.gov/pubmed/33440630
http://dx.doi.org/10.3390/cancers13020238

Ejemplares similares